About Caisson Biotech

Caisson Biotech, LLC is a wholly owned subsidiary of Heparinex, L.L.C., an Oklahoma City-based biotech company which produces a recombinant form of heparosan, a naturally-occurring sugar molecule in the body.  Heparinex also has patented a variety of uses for heparosan including its use as a drug delivery vehicle. It licensed the rights to the drug delivery application to Caisson Biotech in February 2009 which was created for this purpose.

Value Proposition

HEPylation™ benefits to drug developers

  • Opens new markets for their drugs
  • Facilitates re-tooling of their existing drugs for market life extension
  • Improves their drugs’ PK performance

Providing a paradigm shift in patient care and better compliance in multiple therapeutic areas.

Drug Development Opportunities

The HEPylation™ bio-superior drug delivery system is suitable for

  • Joint development with drug developers with their own drug candidates
  • Drug developers wanting to license our HEPylated™ drug candidates
  • Drug developers wanting the supply of the heparosan molecule and rights to use the HEPylation™ system for their own drug conjugate development program

Management

Paul DeAngelis, Ph.D.
Chief Scientist

John HoopingarnerJohn Hoopingarner
President

 

Gregory Pogue, Ph.D.Gregory Pogue, Ph.D.
Vice President, Regulatory

 

Caisson Biotech, LLC, is an Emergent Technologies Inc. (ETI) portfolio company.

About Emergent Technologies, Inc.

Headquartered in Austin, Texas, Emergent Technologies, Inc. (ETI) is a life sciences and medical technology investment and management company which provides early stage funding and development for scientific discoveries originating at universities and research institutions.  The Company creates value by transforming scientific breakthroughs into technology platforms with multiple applications.  ETI's unique innovation process enables the Company to select promising scientific discoveries for development, maximize the value of intellectual property and manage both cost and risk associated with the commercial development of early stage technologies.  ETI is dedicated to turning research into revenue and, in the process, introducing compelling solutions to meet important market needs. For more information, visit the company website www.etibio.com